This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NMS / Neuromedin-S · Western blot design guide
Design a Western Blot for NMS
Real validated NMS Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-NMS WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
NMS Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~17.7 kDa | |
| Gel | 15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Cleaved | |
| Caveat | Peptide-blocking control | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 1 isoform(s) |
Section 1
Real Curated NMS Western Blot Protocols
The A15072-2 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | various cells (catalog A15072-2) |
| Gel % | 15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.2 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A15072-2 · 1:1000 (catalog A15072-2) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected NMS Western Blot Band Size?
NMS has a predicted 17.7 kDa precursor; secretion and cleavage could affect detection and size, but no apparent band size or migration effect is demonstrated.
| Band near 17.7 kDa | consistent with the predicted full-length precursor, pending identity controls |
| Band below 17.7 kDa | could reflect signal-peptide or propeptide cleavage |
| Small fragment bands | could reflect cleavage at paired basic residues |
| Little or no band in whole-cell lysate | consistent with secretion |
💡Expected NMS appearanceThe full-length NMS precursor is predicted at 17.7 kDa; cleavage may produce smaller species, but no empirical band size or migration pattern is supplied, so confirm band identity with appropriate controls.
| Predicted full-length mass | places the precursor at 17.7 kDa before processing |
| Signal peptide at residues 1–26 | cleavage can yield a smaller product than the full-length precursor |
| Propeptide at residues 27–69 | processing can yield a smaller mature product |
| Cleavage at paired basic residues | can generate smaller peptide products of unspecified mass |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | NMS is secreted | check conditioned medium alongside lysate |
| Band lower than expected | signal-peptide or propeptide cleavage may have occurred | check whether the antibody recognizes the retained region |
| Multiple bands | processing at paired basic residues may produce different fragments | use peptide competition and compare lysate with conditioned medium |
| Weak or no signal | secreted NMS may be scarce in the sampled lysate | test conditioned medium and a suitable positive control |
| Fragments below expected size | NMS undergoes proteolytic processing | check antibody epitope location and use peptide competition to assess identity |
Experiment evidence
Western blot images showing NMS band
A15072-2 · NMS
A15072-2 · NMS
A15072-1 · NMS
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for NMS Western blot
🧪For positive controls for NMS in Western blot, you can use conditioned medium from a confirmed NMS-expressing source, but no HPA-positive tissue or cell is supplied.
Positive control: No high/medium HPA tissue identified
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: Because NMS is secreted, conditioned medium may give a better signal than whole-cell lysate; HPA provides no tissue controls.
HPA tissue expression evidence for NMS
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Section 3
Advanced NMS Western Blot Tips
Deeper troubleshooting and optimisation questions for NMS, answered from its protein features.
How should NMS band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Does NMS have alternative isoforms to distinguish?
Isoforms · The supplied UniProt features list one isoform and no alternative sequence. They do not support assigning multiple bands to splice isoforms; consider precursor processing and antibody recognition when interpreting them.
Do annotated modifications prove a band shift?
PTM · The linked UniProt record describes protein features. A modification annotation alone does not demonstrate a visible shift; retain any condition or experimental qualifier attached to it.
Does this guide establish induction of NMS?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for NMS?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A15072-2 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How can NMS processing affect quantitation?
Quantitation · If the antibody detects more than one NMS form, decide which band represents the form of interest before quantifying. UniProt lists a precursor, a signal peptide, a propeptide, and basic-residue cleavage; an antibody’s epitope determines which resulting forms it can measure.
Why might an NMS band differ from 17.7 kDa?
Interpretation · 17.7 kDa is the predicted mass of the 153-residue precursor. UniProt lists a signal peptide at residues 1–26, a propeptide at 27–69, and cleavage on pairs of basic residues. Processing could yield products with different masses, but these features alone do not predict a visible band or its apparent size.
Detection depends on which sequence the antibody recognizes. An antibody against residues 1–26 or 27–69 may behave differently from one recognizing a region retained after processing. Check the antibody epitope against the UniProt precursor coordinates before interpreting a band.
UniProt lists an asparagine amide at position 141, numbered on the 153-residue precursor. Keep that coordinate when comparing antibody or paper numbering. The modification is relevant to peptide identity, but its presence alone does not establish a visible Western blot shift.
UniProt describes NMS as secreted and lists a signal peptide at residues 1–26. Consider whether the tested material contains secreted NMS or its precursor, and match the antibody epitope to the form expected in that material.
Compare bands with the 17.7 kDa precursor prediction and the listed processing features: signal peptide 1–26, propeptide 27–69, and cleavage on pairs of basic residues. The supplied features do not identify the size of each product, so a band cannot be assigned to a specific NMS form by size alone.
Detection depends on which sequence the antibody recognizes. An antibody against residues 1–26 or 27–69 may behave differently from one recognizing a region retained after processing. Check the antibody epitope against the UniProt precursor coordinates before interpreting a band.
UniProt lists an asparagine amide at position 141, numbered on the 153-residue precursor. Keep that coordinate when comparing antibody or paper numbering. The modification is relevant to peptide identity, but its presence alone does not establish a visible Western blot shift.
UniProt describes NMS as secreted and lists a signal peptide at residues 1–26. Consider whether the tested material contains secreted NMS or its precursor, and match the antibody epitope to the form expected in that material.
Compare bands with the 17.7 kDa precursor prediction and the listed processing features: signal peptide 1–26, propeptide 27–69, and cleavage on pairs of basic residues. The supplied features do not identify the size of each product, so a band cannot be assigned to a specific NMS form by size alone.
Boster reagents
NMS Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-Neuromedin-S NMS Antibody
Cat # A15072-2
Real WB data
Anti-Neuromedin-S NMS Antibody
Cat # A15072-1
Two the supplier anti-NMS antibodies list Human, Mouse, and Rat reactivity and include WB images. A15072-1 documents HeLa, HCT116, A549, PC12, and CT26 whole-cell lysates at 1:500; A15072-2 reports various cells at 1:1000 without naming them.
Which to pick: Both have WB images and the same listed reactivity. Choose A15072-1 if its named lysates and 1:500 dilution suit your experiment. A15072-2 shows a 1:1000 example, but its caption does not identify the tested cells.
Source: BosterBio NMS gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q5H8A3.
- Human Protein Atlas. NMS tissue expression.
- PMC5110656 — target-verified WB comparison
- PMC9655409 — target-verified WB comparison